11 research outputs found
Guidelines for Small-Scale Production and Purification of Hepatitis B Surface Antigen Virus-Like Particles from Recombinant Pichia pastoris.
Virus-like particle (VLP)-based vaccines have been in the market since decades
for preventing viral infection and have proven their usefulness also in other
areas of biotechnology. Here, we describe in detail simple small-scale production
and purification procedures for the generation of hepatitis B surface antigen
(HBsAg) VLPs using Pichia pastoris as expression host. This protocol may also be
applicable with variations to other HBsAg-based VLPs additionally carrying
antigens of other pathogens
Advanced Nanobiomedical Approaches to Combat Coronavirus Disease of 2019
New infectious diseases are making themselves known as the human population grows, expands into new regions, and becomes more dense, increasing contact with each other and animal populations. Ease of travel has also increased infectious disease transmission and has now culminated into a global pandemic. The emergence of the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARSâCoVâ2) in December 2019 has already infected over 83.7 million people and caused over 1.8 million deaths. While there have been vaccine candidates produced and supportive care implemented, the world is impatiently waiting for a commercially approved vaccine and treatment for the coronavirus disease of 2019 (COVIDâ19). The different vaccine types investigated for the prevention of COVIDâ19 all have great promise but face safety obstacles that must be first addressed. Some vaccine candidates of key interest are whole inactivated viruses, adenoâassociated viruses, virusâlike particles, and lipid nanoparticles. This review examines nanobiomedical techniques for combatting COVIDâ19 in terms of vaccines and therapeutics